Literature DB >> 16408096

JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.

J L Vizmanos, C Ormazábal, M J Larráyoz, N C P Cross, M J Calasanz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16408096     DOI： 10.1038/sj.leu.2404086

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

2.  JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.

Authors:  Yoko Edahiro; Soji Morishita; Kochi Takahashi; Yumi Hironaka; Yuriko Yahata; Yoshitaka Sunami; Shuichi Shirane; Miyuki Tsutsui; Masaaki Noguchi; Michiaki Koike; Kiyotoshi Imai; Keita Kirito; Naohiro Noda; Yuji Sekiguchi; Satoshi Tsuneda; Akimichi Ohsaka; Marito Araki; Norio Komatsu
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

3.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Authors:  Hadrian Szpurka; Ramon Tiu; Gurunathan Murugesan; Samer Aboudola; Eric D Hsi; Karl S Theil; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

4.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.

Authors:  A Tefferi; A Pardanani; K-H Lim; O Abdel-Wahab; T L Lasho; J Patel; N Gangat; C M Finke; S Schwager; A Mullally; C-Y Li; C A Hanson; R Mesa; O Bernard; F Delhommeau; W Vainchenker; D G Gilliland; R L Levine
Journal:  Leukemia       Date:  2009-03-05       Impact factor: 11.528

Review 5.  Jak-2 positive myeloproliferative neoplasms.

Authors:  Pablo J Muxí; Ana Carolina Oliver
Journal:  Curr Treat Options Oncol       Date:  2014-06

6.  Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.

Authors:  Jacek Treliński; Krzysztof Chojnowski; Barbara Cebula-Obrzut; Piotr Smolewski
Journal:  Med Oncol       Date:  2012-03-15       Impact factor: 3.064

7.  Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.

Authors:  Nicola Cascavilla; Valerio De Stefano; Fabrizio Pane; Alessandro Pancrazzi; Alessandra Iurlo; Marco Gobbi; Francesca Palandri; Giorgina Specchia; A Marina Liberati; Mariella D'Adda; Gianluca Gaidano; Rajmonda Fjerza; Heinrich Achenbach; Jonathan Smith; Paul Wilde; Alessandro M Vannucchi
Journal:  Drug Des Devel Ther       Date:  2015-05-18       Impact factor: 4.162

Review 8.  Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Alessandro Rambaldi; Costanza Bogani; Tiziano Barbui
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

Review 9.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.